Biogen, Eisai are pushing for another accelerated Alzheimer's OK — this time for BAN2401
Now that the door at the FDA has been opened wide for Alzheimer’s drugs that can demonstrate a reduction in amyloid, Biogen and its partners at Eisai are pushing for a quick OK on the next drug to follow in the controversial path of aducanumab.
In a presentation to analysts, Eisai neurology chief Ivan Cheung outlined some bullish expectations for their newly-approved treatment and set the stage for what he believes will be a fast follow for BAN2401 (lecanemab) — after a dry spell in new drug development that’s lasted close to 20 years.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 128,900+ biopharma pros reading Endpoints daily — and it's free.